NCT06925542 - A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 10, 2025

Primary Completion Date

December 31, 2031

Study Completion Date

December 31, 2031

Conditions

SLE (Systemic Lupus)Lupus Erythematosus, SystemicLupus NephritisSystemic SclerosisInflammatory Myopathy, IdiopathicMyositisDiffuse Cutaneous Systemic Sclerosis

Interventions

BIOLOGICAL

CTX112

CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)

Trial Locations (8)

27599

RECRUITING

Research Site 5, Chapel Hill

30625

NOT_YET_RECRUITING

Research Site 3, Hanover

52242

NOT_YET_RECRUITING

Research Site 8, Iowa City

63110

RECRUITING

Research Site 2, Chicago

63130

RECRUITING

Research Site 1, St Louis

86156

NOT_YET_RECRUITING

Research Site 7, Augsburg

94063

RECRUITING

Research Site 4, Redwood City

02118

RECRUITING

Research Site 6, Boston